To include your compound in the COVID-19 Resource Center, submit it here.

AveXis details SMA gene therapy plans, proposes follow-on

AveXis Inc. (NASDAQ:AVXS) detailed plans Tuesday to expand its clinical development program for spinal muscular atrophy gene therapy candidate AVXS-101 via four additional clinical trials. The company also proposed to raise $400 million in a follow-on underwritten by Goldman Sachs, Jefferies, BofA Merrill Lynch and BMO

Read the full 460 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE